The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl； R2 represents hydrogen； halogen； alkenyl； alkynyl； -alkenylaryl； -alkenylheteroaryl； alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, &mdash；C(O)OH and &mdash；C(O)O-alkyl； carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, &mdash；C(O)OH and &mdash；C(O)O-alkyl； -alkylcarbocyclyl； -alkylheterocyclyl； aryl； heteroaryl； heterocyclyl； -alkylaryl； -alkyl(aryl)2, -alkylheteroaryl； -aryl-heteroaryl； -heterocyclyl-aryl； -aryl-aryl； -heteroaryl-aryl； -heteroaryl-heteroaryl, and &mdash；C(O)R4； R3 represents halogen； alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, &mdash；C(O)OH and &mdash；C(O)O-alkyl； aryl； heteroaryl； &mdash；C(O)R5； R4 and R5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R3 may not be &mdash；C(O)R5.
